Canopy Growth Taps $250M ATM Equity Program as Q1 FY26 Revenues Jump 43%
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Canopy Growth Corporation (ticker: CGC) is a publicly traded cannabis company headquartered in Smiths Falls, Ontario. Founded in 2013 as Tweed Marijuana Inc., the company became the first federally regulated, licensed cannabis producer in North America to list on the Toronto Stock Exchange (“WEED”) and the New York Stock Exchange (“CGC”). Canopy Growth cultivates and sells medicinal and recreational cannabis and hemp products through a portfolio that includes Doja, 7ACRES, Tweed, and Deep Space, as well as non-THC offerings under Martha Stewart CBD and Storz & Bickel vaporizers. Its U.S. operations are held in a separately operated entity, Canopy USA, which is not consolidated into the Canadian parent’s financial statements.
Corporate Structure and Operations
Canopy Growth employs between 1,001 and 5,000 people across its global operations. Key elements of its corporate structure include:
- A network of cultivation and processing facilities in Canada and Europe
- An unconsolidated holding company, Canopy USA, serving the U.S. THC market
- Retail operations under subsidiary Tweed Inc. and the Tokyo Smoke brand, where private-sector retail is permitted
- Transfer agent services provided by Odyssey Trust Company
Cannabis Industry by Richard T
Developments and News
On June 6, 2024, Canopy Growth established a US$250 million at-the-market equity program to support potential acquisitions, investments, and general corporate purposes. Proceeds may also be used for working capital and debt repayment.
On August 8, 2025, the company released its Q1 FY 2026 financial results. Canada adult-use cannabis net revenue grew by 43% year-over-year, driven by broader distribution and consumer uptake of new products such as Claybourne infused pre-roll joints. By that date, Canopy Growth had achieved US$17 million of an annualized US$20 million cost-savings target, reducing SG&A expenses by 21% year-over-year. Supply chain improvements in international markets are expected to enhance throughput and margins in European operations during the second half of FY 2026.
In 2025, Canopy Growth appointed Miles Worne as Managing Director of European Markets to lead commercial strategy and market execution across the region. In August 2025, Thomas Stewart was named Interim Chief Financial Officer, bringing over 20 years of operational finance and accounting leadership.
Financial and Strategic Analysis
As of August 11, 2025, CGC shares traded on NASDAQ at US$1.62, up 29.60% on the day, with a volume of 25,007,278. Key metrics from Yahoo Finance and company filings include:
| Metric | Value |
|---|---|
| Previous Close | US$1.05 |
| Day’s Range | US$1.10 – US$1.43 |
| 52-Week Range | US$0.77 – US$7.21 |
| Market Capitalization (intraday) | US$333 million |
| Volume (Avg.) | 9,467,232 |
| Price/Sales (ttm) | 0.84 |
| Price/Book (mrq) | 0.66 |
| Total Cash (mrq) | US$131.6 million |
| Total Debt/Equity (mrq) | 71.5% |
| Revenue (ttm) | US$269 million |
| Net Income (ttm) | –US$604.1 million |
| Profit Margin | –222.35% |
Strategically, Canopy Growth is focusing on cost discipline, supply chain resilience, and brand expansion. The ATM equity program provides balance-sheet flexibility for targeted acquisitions. European market leadership is being pursued through dedicated commercial management, while U.S. THC exposure is maintained via Canopy USA without consolidating associated liabilities.
Market Position and Industry Context
Canopy Growth operates in two primary segments: adult-use cannabis in Canada and medical cannabis in global markets including Europe and Australia. In Canada, it competes with both licensed producers and provincially authorized retail chains. Internationally, regulatory frameworks vary, requiring tailored market approaches. The company’s brand diversification—ranging from potencies and delivery formats to non-THC wellness products—aims to address multiple consumer and patient segments. Its position as an early mover and scale cultivator is complemented by ongoing investments in vaporizer technology and a growing portfolio of infused products.
tl;dr
• On August 8, 2025, Canopy Growth reported Q1 FY 2026 results showing a 43% year-over-year rise in Canada adult-use cannabis net revenue and US$17 million of cost savings achieved.
• A US$250 million at-the-market equity program, established June 6, 2024, remains available to fund acquisitions and strengthen the balance sheet.
• Supply chain improvements are slated to boost margins in European markets in the second half of FY 2026.
• Miles Worne was appointed to lead European commercial operations, and Thomas Stewart became Interim CFO in August 2025.